drugset
drugset / Trial / NCT06104839

Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

NCT06104839 ↗

Phase 2 Recruiting 73 enrolled NEXTGEN Bioscience
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

Timeline

Start
2024-09-01
Primary completion
2026-10-31
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject NXC736 Unknown — Oral

Indications

alopecia areata